Affirmed Therapeutics BV (NASDAQ:AFMD)’s share price was up 4.8% during trading on Friday . The company traded as high as $2.89 and last traded at $2.85, with a volume of 52,414 shares trading hands. The stock had previously closed at $2.72.

A number of equities analysts have recently issued reports on the stock. BMO Capital Markets assumed coverage on shares of Affirmed Therapeutics BV in a research report on Monday, April 11th. They set an “outperform” rating and a $7.00 target price on the stock. Leerink Swann reiterated an “outperform” rating and set a $8.00 target price on shares of Affirmed Therapeutics BV in a research report on Friday, April 1st. Wells Fargo & Co. reiterated a “buy” rating on shares of Affirmed Therapeutics BV in a research report on Wednesday, May 18th. Finally, Jefferies Group reduced their target price on shares of Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Thursday, May 19th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Affirmed Therapeutics BV has an average rating of “Buy” and a consensus target price of $9.46.

The firm’s market capitalization is $96.46 million. The firm has a 50 day moving average price of $3.07 and a 200-day moving average price of $3.72.

Affirmed Therapeutics BV (NASDAQ:AFMD) last released its quarterly earnings results on Wednesday, May 18th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.08. The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.88 million. The business’s revenue for the quarter was down 24.0% compared to the same quarter last year. On average, analysts predict that Affirmed Therapeutics BV will post ($0.95) EPS for the current year.

A hedge fund recently raised its stake in Affirmed Therapeutics BV stock. Tekla Capital Management LLC boosted its stake in shares of Affirmed Therapeutics BV (NASDAQ:AFMD) by 29.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 294,213 shares of the biopharmaceutical company’s stock after buying an additional 66,130 shares during the period. Tekla Capital Management LLC owned 0.97% of Affirmed Therapeutics BV worth $2,095,000 as of its most recent filing with the SEC.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.